Home » Stocks » Surface Oncology

Surface Oncology, Inc. (SURF)

Stock Price: $8.69 USD -0.88 (-9.20%)
Updated Oct 26, 2020 12:51 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 346.78M
Revenue (ttm) 39.38M
Net Income (ttm) -25.07M
Shares Out 39.91M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $8.69
Previous Close $9.57
Change ($) -0.88
Change (%) -9.20%
Day's Open 9.50
Day's Range 8.68 - 9.56
Day's Volume 373,669
52-Week Range 1.36 - 10.25

More Stats

Market Cap 346.78M
Enterprise Value 282.63M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 39.91M
Float 31.43M
EPS (basic) -0.82
EPS (diluted) -0.86
FCF / Share -1.80
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 567,365
Short Ratio 0.62
Short % of Float 1.81%
Beta 2.39
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.81
PB Ratio 3.61
Revenue 39.38M
Operating Income -25.91M
Net Income -25.07M
Free Cash Flow -60.20M
Net Cash 64.16M
Net Cash / Share 1.61
Gross Margin -93.35%
Operating Margin -65.81%
Profit Margin -63.70%
FCF Margin -152.90%
ROA -9.99%
ROE -27.55%
ROIC -25.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(24.28% upside)
Current: $8.69
Target: 10.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-74.15%363.25%93.4%-
Gross Profit15.3659.4212.836.63
Operating Income-57.37-9.15-45.99-18.00
Net Income-54.79-6.60-45.38-17.45
Shares Outstanding27.8519.992.472.39
Earnings Per Share-1.97-0.33-18.35-7.31
Operating Cash Flow-60.14-13.22-12.4241.41
Capital Expenditures-1.54-2.02-1.97-0.84
Free Cash Flow-61.68-15.24-14.4040.58
Cash & Equivalents10716064.3980.24
Total Debt25.04---
Net Cash / Debt81.7216064.3980.24
Book Value56.67103-67.31-26.91
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Surface Oncology, Inc.
Country United States
Employees 49
CEO J. Jeffrey Goater

Stock Information

Ticker Symbol SURF
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SURF
IPO Date April 19, 2018


Surface Oncology, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDAÂ (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.